STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

Home・Elenco Azioni・GlaxoSmithKline PLC

GlaxoSmithKline PLC

Chiusa

SettoreSettore sanitario

1,846.25 0.29

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1841

Massimo

1869.25

Metriche Chiave
By Trading Economics
Entrata	1.2B 1.8B
Vendite	-989M 7.6B
P/E Media del settore	13.387 49.8
EPS	0.465
Rendimento da dividendi	3.47
Margine di Profitto	24.105
Dipendenti	66,841
EBITDA	577M 2.8B

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+7.24% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	3.47% 2.25%
Utili prossimi	29 lug 2026
Prossima data del Dividendo	9 lug 2026
Prossima data del' Ex Dividendo	14 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-4.2B 76B
Apertura precedente	1845.96
Chiusura precedente	1846.25

Notizie sul Sentiment di mercato

By Acuity

56%

44%

271 / 347 Classifica in Healthcare

GlaxoSmithKline PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 06:42 UTC

Utili

GSK Earnings Boosted by Higher Specialty Medicine Sales

6 mag 2026, 13:35 UTC

Discorsi di Mercato

GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

29 apr 2026, 10:39 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

29 apr 2026, 10:06 UTC

Discorsi di Mercato

Utili

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 apr 2026, 10:02 UTC

Discorsi di Mercato

Utili

GSK Makes Ideal Start for New CEO -- Market Talk

29 apr 2026, 06:07 UTC

Utili

GSK PLC Sees 70p 2026 Dividend Payout

29 apr 2026, 06:07 UTC

Utili

GSK PLC Declares Dividend of 17p

29 apr 2026, 06:07 UTC

Utili

GSK PLC Free Cash Flow of GBP0.8B

29 apr 2026, 06:06 UTC

Utili

GSK PLC Cash Generated From Operations GBP1.4B

29 apr 2026, 06:06 UTC

Utili

GSK PLC 1Q General Medicines Sales GBP2.3B

29 apr 2026, 06:06 UTC

Utili

GSK PLC 1Q Vaccines Sales GBP2.1B

29 apr 2026, 06:06 UTC

Utili

GSK PLC 1Q Specialty Medicines Sales GBP3.2B

29 apr 2026, 06:05 UTC

Utili

Analysts Saw GSK PLC 1Q Net Profit at GBP1.74B

29 apr 2026, 06:04 UTC

Utili

Analysts Saw GSK 1Q Adjusted Operating Profit of GBP2.46B

29 apr 2026, 06:04 UTC

Utili

GSK PLC 1Q Adjusted Operating Profit GBP2.65B

29 apr 2026, 06:04 UTC

Utili

Analysts Saw GSK PLC Core EPS of 43.3p

29 apr 2026, 06:04 UTC

Utili

Analysts Saw GSK PLC 1Q Turnover at GBP7.58B

29 apr 2026, 06:04 UTC

Utili

GSK PLC 1Q Adj EPS 46.50p

29 apr 2026, 06:01 UTC

Utili

GSK PLC Sees 2026 Adjusted EPS Growth of 7%-9%

29 apr 2026, 06:01 UTC

Utili

GSK PLC Sees 2026 Adjusted Oper Pft Growth of 7%-9%

29 apr 2026, 06:01 UTC

Utili

GSK PLC Sees 2026 Turnover Growth of 3%-5%

29 apr 2026, 06:01 UTC

Utili

GSK PLC Backs 2026 View

29 apr 2026, 06:00 UTC

Utili

GSK PLC 1Q EPS 42.6p

29 apr 2026, 06:00 UTC

Utili

GSK PLC 1Q Turnover GBP7.63B

29 apr 2026, 06:00 UTC

Utili

GSK PLC 1Q Pretax Pft GBP2.14B

29 apr 2026, 06:00 UTC

Utili

GSK PLC 1Q Oper Pft GBP2.29B

29 apr 2026, 06:00 UTC

Utili

GSK PLC 1Q Net Pft GBP1.74B

15 apr 2026, 06:12 UTC

Acquisizioni, Fusioni, Takeovers

GSK Completes Acquisition of 35Pharma

10 apr 2026, 10:43 UTC

Discorsi di Mercato

GSK Could Report Weak General Medicines Results -- Market Talk

31 mar 2026, 14:02 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics Will Continue Supplying Products Previously Manufactured at Site to GSK Under Terms of Agreement

Confronto tra pari

Modifica del prezzo

GlaxoSmithKline PLC Previsione

Obiettivo di Prezzo

By TipRanks

7.24% in crescita

Previsioni per 12 mesi

Media 1,976.36 GBX 7.24%

Alto 2,630 GBX

Basso 1,500 GBX

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per GlaxoSmithKline PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

13 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 13 che hanno fornito valutazioni azionarie a GlaxoSmithKline PLC - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

271 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.